Icecure Medical is trading 5.95% down at $2.37, with continued caution after the August 12 quarterly earnings miss contributing to the decline.
- Losses extend after declines on August 19, August 18, and August 17.
- No fresh bearish company announcement was identified on August 20; the latest company news was positive IRB approval for its ChoICE breast-cancer study.
- Weaker major U.S. indexes may be adding pressure; healthcare strength and the study approval do not explain the selling.